Barchart.com
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Investment Tools And Research To Help Make You A More Confident And Profitable Trader. FREE 30 Day Trial
Menu
Stocks | Futures | Watchlist | News | More
 
or
Watchlist | Portfolio | Dashboard
Site News
Contact
Market:
Faster, Cleaner, Better.
Menu

Immunitybio Inc (IBRX)

Immunitybio Inc (IBRX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
News & Headlines for [[ item.sessionDateDisplayLong ]]
Notes
Alerts
Watch
Help
Go To:
Breaking Through: Systemic Genetic Medicines for Hard-to-Treat Cancers FinancialNewsMedia - Wed Jul 9, 7:30AM CDT

EQNX::TICKER_START (NYSE:CLDI),(NASDAQ:VRTX),(NASDAQ:IBRX),(NASDAQ:CRSP),(NASDAQ:CTMX) EQNX::TICKER_END

CLDI : 0.7600 (-23.85%)
CRSP : 56.80 (-3.73%)
CTMX : 2.42 (-6.92%)
VRTX : 468.85 (-2.23%)
IBRX : 2.81 (-2.09%)
Breaking Through: Systemic Genetic Medicines for Hard-to-Treat Cancers Newswire.ca - Wed Jul 9, 7:30AM CDT

/CNW/ -- Each year, approximately 20 million people are diagnosed with cancer, and nearly 10 million lives are lost to the disease worldwide, a toll that is...

CLDI : 0.7600 (-23.85%)
CRSP : 56.80 (-3.73%)
CTMX : 2.42 (-6.92%)
VRTX : 468.85 (-2.23%)
IBRX : 2.81 (-2.09%)
As Public Cancer Funding Wavers, Oncology's Brightest Breakthroughs Are Coming From Industry Newswire.ca - Thu Jun 12, 9:00AM CDT

/CNW/ -- Equity Insider News Commentary – The 2025 ASCO Annual Meeting has wrapped, leaving behind a wave of cautious optimism across the oncology landscape....

ONCY : 1.1800 (+5.83%)
ANIX : 3.14 (unch)
IOVA : 1.8700 (-3.11%)
ONC.TO : 1.60 (+5.96%)
REGN : 567.74 (+1.43%)
IBRX : 2.81 (-2.09%)
ImmunityBio: Q1 Earnings Snapshot AP - Mon May 12, 5:36AM CDT

ImmunityBio: Q1 Earnings Snapshot

IBRX : 2.81 (-2.09%)
ImmunityBio: Q4 Earnings Snapshot AP - Mon Mar 3, 7:06AM CST

ImmunityBio: Q4 Earnings Snapshot

IBRX : 2.81 (-2.09%)
ImmunityBio Surges On FDA Green Light For Expanded Bladder Cancer Vaccine Access — Retail Buzz Intensifies Stocktwits - Thu Feb 20, 2:32AM CST

The company said that Merck’s TICE BCG shortages have created a significant hurdle for bladder cancer treatment.

MRK : 83.36 (-0.79%)
IBRX : 2.81 (-2.09%)
Optimism in War on Cancer on the Rise, as Biotech Companies Roll Out More Wins FinancialNewsMedia - Tue Feb 18, 10:24AM CST

Vancouver, BC – February 18, 2025 – USA News Group News Commentary – Despite optimism coming from the launch of Project Stargate (a $500 billion investment in AI data centers), there is still cause...

ONCY : 1.1800 (+5.83%)
ALLO : 1.2800 (+1.59%)
VRCA : 0.8066 (-7.55%)
ONC.TO : 1.60 (+5.96%)
OSTX : 1.7000 (+1.80%)
IBRX : 2.81 (-2.09%)
Optimism in War on Cancer on the Rise, as Biotech Companies Roll Out More Wins BayStreet.ca - Tue Feb 18, 8:05AM CST

Issued on behalf of Oncolytics Biotech Inc. VANCOUVER – USA News Group News Commentary – Despite optimism coming from the launch of Project Stargate (a $500 billion investment in AI data centers),...

ALLO : 1.2800 (+1.59%)
ONCY : 1.1800 (+5.83%)
VRCA : 0.8066 (-7.55%)
ONC.TO : 1.60 (+5.96%)
IBRX : 2.81 (-2.09%)
OSTX : 1.7000 (+1.80%)
ImmunityBio Stock Soars On BeiGene Tie-Up, Supply Deal: Retail Gets Dose Of Optimism Stocktwits - Wed Jan 29, 12:52PM CST

The study will evaluate a combination therapy using BeiGene’s tislelizumab and ImmunityBio’s Anktiva for certain patients with advanced or metastatic non-small cell lung cancer

ONC : 250.30 (-1.22%)
IBRX : 2.81 (-2.09%)
The Immunotherapy Boom: What It Means for the Future of Cancer Treatment BayStreet.ca - Thu Dec 26, 2024

Issued on behalf of Oncolytics Biotech Inc. VANCOUVER – USA News Group News Commentary – Immunotherapy is revolutionizing oncology by harnessing the power of the immune system to fight cancer...

ONCY : 1.1800 (+5.83%)
AUTL : 2.47 (-0.40%)
IOVA : 1.8700 (-3.11%)
ABBV : 192.45 (-1.31%)
ONC.TO : 1.60 (+5.96%)
IBRX : 2.81 (-2.09%)

Barchart Exclusives

Gold's Bull Run: Seasonal Strength Meets Conflicting COT Report—Are You In? Barchart - Sat Jul 12, 2:47PM CDT
Gold's all-time high $3,509.9! Central banks bought big, but the COT report waves a red flag. Seasonal gains await—Market players, read or regret! Read more
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar
[[ data.userDate ]]
[[ data.eventTime | date: 'EEE, MMM dd, yyyy h:mm a' ]] [[ zone ]]
Reserve Your Spot